Skip to content
‹ Back to IndustriesSciences

Japan’s Radioactive Water Release Won’t Impact Neighboring Countries, Despite China’s Opposition and Ban on Japanese Seafood

With news of China banning seafood from Japan, the debate around nuclear energy has always been fraught with concerns about safety, especially following high-profile incidents like Fukushima. However, it’s worth noting that nuclear plants across the world, including officials in countries vocally concerned about Japan’s handling of tritiated water, routinely have their own radioactive…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Alexandra Simon · · ChinaFukushimaJapanRadioactive Release
Share

Key takeaways

01

With news of China banning seafood from Japan, the debate around nuclear energy has always been fraught with concerns about safety, especially following high-profile incidents like Fukushima.

02

However, it’s worth noting that nuclear plants across the world, including officials in countries vocally concerned about Japan’s handling of tritiated water, routinely have their own radioactive…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

With news of China banning seafood from Japan, the debate around nuclear energy has always been fraught with concerns about safety, especially following high-profile incidents like Fukushima. However, it’s worth noting that nuclear plants across the world, including officials in countries vocally concerned about Japan’s handling of tritiated water, routinely have their own radioactive waste responsibilities. 

It’s easy to get caught in the emotion and politics of the situation, especially when it involves terms like “radioactive release,” but understanding the science and safety protocols is crucial. Independent organizations like the International Atomic Energy Agency (IAEA) provide not just oversight but also expertise in making sure that any release is carried out to stringent safety standards. For instance, the tritium levels being released from Fukushima meet standards set by the World Health Organization and the Japanese government. The release of tritiated water is a monitored, understood, and internationally sanctioned activity that comes as a part of the territory with nuclear energy. 

To further explain the safety of this effort and how public perception impacts nuclear outlook is Ken Petersen, President of the American Nuclear Society. He brings years of experience and knowledge on the subject. Previously he was the vice president for nuclear fuels at Exelon Generation Company (EGC) for more than 12 years. He even worked on a contract with the U.S. Department of Energy, and has a Bachelor’s and Master’s in nuclear engineering from the University of Wisconsin.

Petersen mentioned that Japan’s release of tritiated water — water that’s been heavily treated, undergoes safety protocols set by global standards. He further added that China’s opposition bears hypocrisy given that they, too, have also released radioactive water under those same guidelines.

Petersen’s Thoughts on Radioactive Water Release

“Sure. So, I mean, the site is no longer has room for expanded storage. So, something has to happen with the tritiated water. It’s been, you know, filtered twice and, you know, what is remaining is a little bit of tritium that’s going to be blended down even further and released. So, it’s going to be monitored and released. The IAEA has reviewed it. They will have somebody there monitoring it to assure that everything is done appropriately. So, this is no different than any other plant. 

“So, when you have a radioactive release, it is monitored and it meets the criteria. And it’s, you know, one-seventh of the World Health Organization levels. And it’s a fortieth of what the Japanese government limits are. So, it’s a very understood and very small amount. Well, there’s a history from their neighbors where, you know, some of their neighbors don’t get along very well. But the neighbors who are speaking loudly also have reactors where they’ll do the exact same thing. You know, they will have tritium releases. They will be monitored and be well within safety levels. Yeah, this shouldn’t impact that at all. So, this is a very unfortunate situation, you know, that the Fukushima plants had the earthquake and following tsunami. And it resulted with this large storage of tritiated water and it is just a monitored release. It should have no impact on the outlook for new nuclear.”

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

AS
Alexandra SimonFreelance Writer

Alexandra is a freelance writer based in New York City. She's a big fan of true crime television and the Oxford comma. She has a background in local news reporting, beat reporting, magazine writing, SEO writing, and copywriting.

B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Agilent's new 5987A GC/MS takes aim at costly sample reruns

Agilent's new 5987A GC/MS takes aim at costly sample reruns

Agilent’s 5987A GC/MSD adds vendor-claimed up to 25% faster scanning and a wider detector range alongside GC Assist diagnostics tracking 60-plus parameters. Its design focuses on taking injections out of workflows to limit reruns. With helium spot prices reportedly doubling after the March 2026 disruption, avoided reruns can save gas, but EPA criteria checks and ISO/IEC 17025 verification still come first.

  • 01Injection-cutting features can matter most: MassHunter’s simultaneous dSIM/Scan to combine SIM quantitation and library-searchable full scan in one run, and Agilent’s claim of an order-of-magnitude wider dynamic range that could reduce dilution reinjections if it holds up in routine use.
  • 02Onboard diagnostics pay back unevenly. Labs that find faults by failing QC batches stand to gain the most, while labs on comprehensive service contracts may mainly change which contract tier they buy.
  • 03The up-to-40% energy cut applies with the IDP-4 pump, so bid scoring should confirm the quoted configuration before crediting the savings.

Nov 10, 2026

Adding Genmab's petosemtamab to Keytruda cut head and neck cancer death risk in half

Adding Genmab's petosemtamab to Keytruda cut head and neck cancer death risk in half

Genmab's petosemtamab, added to Merck's Keytruda, cut the risk of death by 50% in 699 first-line head and neck cancer patients. The trial held regardless of HPV status. Full data will be presented at an upcoming medical meeting.

  • 01In a cancer where median survival runs about 10 to 12 months, adding petosemtamab to Keytruda halved the risk of death at the first interim look.
  • 02The benefit held regardless of HPV status, supporting use in PD-L1-positive patients without separating by HPV status.
  • 03The figure to watch at the full-data presentation is median overall survival in each arm, because the topline release reports only the hazard ratio.

Nov 9, 2026

UCB commits to Veeva Vault CRM platform

UCB commits to Veeva Vault CRM platform

UCB has committed to Veeva Vault CRM, which Veeva’s release presents as an agentic CRM platform to drive unified engagement worldwide. UCB and Veeva executives describe it as a stable foundation for UCB’s commercial strategy, while the AI claims, including the Agentic Call Report, come from Veeva’s product description. No go-live date or financial terms were given.

  • 01The executive statements focus on Vault CRM as a foundation. The AI pitch, including the Agentic Call Report, comes from Veeva’s product description.
  • 02Veeva says the Agentic Call Report turns field call records into "Commercial Evidence" about treatment barriers that went unseen before. If it works as described, call reports gain value when analyzed at scale.
  • 03No go-live date or financial terms were disclosed. A go-live date or first-market rollout from UCB would show whether a worldwide migration is moving.

Nov 7, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

AS
Alexandra Simon

Freelance Writer

Alexandra is a freelance writer based in New York City. She's a big fan of true crime television and the Oxford comma. She has a background in local news reporting, beat reporting, magazine writing, SEO writing, and copywriting.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512